Want to see HK:0570 full AI Analyst Report?
0570 Stock Chart & Stats
HK$1.41
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$1.41
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.32 - HK$2.68
Previous CloseN/A
Volume9.79M
Average Volume (3M)51.13M
Market Cap
HK$7.25B
Enterprise ValueHK$10.41K
Total Cash (Recent Filing)HK$5.16B
Total Debt (Recent Filing)HK$2.49B
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)-0.07
Shares Outstanding5,035,802,000
10 Day Avg. Volume46,853,920
30 Day Avg. Volume51,130,115
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.64
P/FCF Ratio4.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$14.24B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and falling total debt into 2024–2025 give the company durable financial flexibility. A conservative balance sheet reduces refinancing risk during downturns, supports capital allocation choices, and provides a buffer that helps sustain operations while earnings recover.
Strong Recent Operating & Free Cash FlowPositive OCF and FCF in 2024–2025 indicate the business still converts operations into cash despite weaker reported earnings. This cash generation can fund working capital, capex, or deleveraging and supports resilience over the medium term if cash conversion remains consistent.
Solid Gross-profit EconomicsMaintaining healthy gross profit suggests core product economics and manufacturing margins remain viable. If management can control SG&A and other below-gross costs, the firm has a structural pathway to restore operating profitability without needing fundamental product repricing.
Bears Say
Earnings Deterioration To Net Loss (2025)A shift to a net loss erodes retained earnings and reduces the firm's ability to reinvest and compound capital. Persistent losses can force cost cutting, dividend reductions, or external financing, weakening long-term growth prospects until profitability is sustainably restored.
Inconsistent Revenue Trends And Recent DeclinesRecurring revenue declines and volatile top-line growth signal weak end-market demand or competitive pressure. Sustained revenue contraction undermines scale economics, makes margin recovery harder, and raises the bar for management to rebuild a durable growth trajectory.
Historical Cash-flow VolatilityHistoric swings in free cash flow increase risk that recent positive cash conversion is cyclical. If FCF reverts or weakens, the company may struggle to fund operations, investment, or dividends without tapping reserves or external financing, harming long-term stability.
China Traditional Chinese Medicine Holdings Co News
0570 FAQ
What was China Traditional Chinese Medicine Holdings Co Ltd’s price range in the past 12 months?
China Traditional Chinese Medicine Holdings Co Ltd lowest stock price was HK$1.32 and its highest was HK$2.68 in the past 12 months.
What is China Traditional Chinese Medicine Holdings Co Ltd’s market cap?
China Traditional Chinese Medicine Holdings Co Ltd’s market cap is HK$7.25B.
When is China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date?
China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.
How were China Traditional Chinese Medicine Holdings Co Ltd’s earnings last quarter?
China Traditional Chinese Medicine Holdings Co Ltd released its earnings results on Mar 20, 2026. The company reported -HK$0.051 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is China Traditional Chinese Medicine Holdings Co Ltd overvalued?
According to Wall Street analysts China Traditional Chinese Medicine Holdings Co Ltd’s price is currently Overvalued.
Does China Traditional Chinese Medicine Holdings Co Ltd pay dividends?
China Traditional Chinese Medicine Holdings Co Ltd pays a Notavailable dividend of HK$0.086 which represents an annual dividend yield of 0.24%. See more information on China Traditional Chinese Medicine Holdings Co Ltd dividends here
What is China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate?
China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Traditional Chinese Medicine Holdings Co Ltd have?
China Traditional Chinese Medicine Holdings Co Ltd has 5,035,802,000 shares outstanding.
What happened to China Traditional Chinese Medicine Holdings Co Ltd’s price movement after its last earnings report?
China Traditional Chinese Medicine Holdings Co Ltd reported an EPS of -HK$0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.529%.
Which hedge fund is a major shareholder of China Traditional Chinese Medicine Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:0570
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Traditional Chinese Medicine Holdings Co Ltd
China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic of China. The company's product range includes medicinal granules, finished pharmaceutical preparations, pre-portioned decoction materials, and various healthcare products. Furthermore, its operations extend to the cultivation and management of Chinese medicinal herbs, the manufacturing of traditional Chinese medicines, and the trading of pharmaceutical products. It also delivers marketing, advertising, and consulting services related to TCM, and operates retail outlets for pharmaceuticals and decoction products. Property leasing services represent another facet of its business. The company distributes its products to healthcare facilities and retail pharmacies. Established in 1573 and headquartered in Wan Chai, Hong Kong, the firm was formerly known as China Traditional Chinese Medicine Co. Limited before adopting its current name in July 2016.
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Wai Yuen Tong Medicine Holdings Limited
―
Grand Pharmaceutical Group Limited
―
Golden Throat Holdings Group Co Ltd
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―